Assuring the optimal use of serotonin antagonist antiemetics: The process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 771-778

  Nolte, M Jane ^a   Berkery, Regina ^a   Pizzo, Barbara ^a   Baltzer, Lorraine ^a   Grossano, Dennis ^a   Lucarelli, Charles D ^a   Kris, Mark G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; SEROTONIN ANTAGONIST;

ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; COST EFFECTIVENESS ANALYSIS; DRUG USE; HEALTH CARE POLICY; HUMAN; PRIORITY JOURNAL; TREATMENT PLANNING; VOMITING;

EID: 0031941716     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.771     Document Type: Article

References (16)

1. Coates A, Abraham S, Kate SB, et al: On the receiving end -Patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203-208, 1983
2. Kris MG: Rationale for combination antiemetic therapy and strategies for the use of ondansetron in combinations. Semin Oncol 19:61-66, 1992
3. Roila F, Tonato M, Cognetti F, et al: Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675-678, 1991
4. Roila F: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1-5, 1995
5. Hainsworth J, Harvey W, Pendergrass K, et al: A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9:721-728, 1991
6. Roila F, Tonato M, Ballatori E, et al: Ondanstron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 340:96-99, 1992
7. 1996 Drug Topics Redbook. Montvale, NJ, Medical Economics, 1996
8. Beck TM, Hesketh PJ, Madajewicz S, et al: Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:1969-1975, 1992
9. Marty M, Pouillart P, Scholl S, et al: Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821, 1990
10. Lindley C, Bernard S, Fields SM: Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 7:1142-1149, 1989
11. Hesketh P, Beck T, Uhlenhopp M, et al: Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetic potential of the chemotherapy regimen. J Clin Oncol 13:2117-2122, 1995
12. Hesketh PJ, Kris MG, Grunberg SM, et al: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109, 1997
13. Kris MG, Gralla RJ, Tyson LB, et al: Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7:108-114, 1989
14. Kris MG, Gralla RJ, Tyson LB, et al: Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 55:527-534, 1985
15. Lindley CM, Hirsch JD, O'Neill CV, et al: Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331-340, 1992
16. Navari R, Gandara D, Hesketh P, et al: Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13:1242-1248, 1995